Bone Marrow Research / 2013 / Article / Tab 3

Clinical Study

Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation

Table 3

Univariate analysis overall survival and progression-free survival.

VariablesOverall survivalProgression-free survival
HR95% CI HR95% CI

At diagnosis
Age > 45 years1.010.34–2.420.90.870.44–1.980.7
Female versus male0.34
0.15–0.72
<0.004
0.620.34–1.100.1
Albumin ≥ 40.30
0.14–0.61
<0.0009
0.380.21–0.69<0.001
ALC ≥ 0.6 cells/µL0.12
0.06–0.24
<0.0001
0.250.14–0.45<0.0001
Mediastinal ≥ 10 cm2.060.93–4.260.071.870.93–3.510.08
Hemoglobin < 10.5 g/dL3.311.61–6.72<0.0022.161.15–3.89<0.02
Stage 41.140.52–2.860.31.370.71–2.510.3
WBC > 15 cells/µL4.682.24–9.49<0.00013.181.64–5.84<0.001
IPS ≥ 34.202.07–8.66<0.00012.891.59–5.14<0.0006
Limited versus advanced stage0.920.45–1.860.80.730.40–1.300.3
Infused CD34+ stem cells0.830.65–1.040.10.960.80–1.120.6
Pretransplant response (CR versus PR)0.540.16–1.390.20.490.19–1.070.08
At day 15 post-APBHSCT
ALC ≥ 0.5 cells/µL 0.120.05–0.25 <0.00010.210.11–0.37<0.0001
At day 100 post-APBHSCT
Age, continuous0.990.97–1.030.90.950.87–1.110.5
ALC, continuous0.330.16–0.61<0.00010.480.29–0.75<0.0006
ALC ≥ 0.8 cells/µL0.280.15–0.59<0.00010.280.16–0.50<0.0001
AMC, continuous2.161.46–2.92<0.00011.801.24–2.40<0.0001
AMC ≥ 0.63 cells/µL7.553.64–15.93<0.00013.882.12–7.06<0.0001
ALC/AMC, continuous0.030.01–0.10<0.00010.490.37–0.63<0.0001
ALC/AMC ≥ 1.30.070.03–0.15<0.00010.180.10–0.32<0.0001
ANC, continuous1.100.86–1.370.51.010.81–1.220.9
Hgb, continuous0.930.76–1.130.50.960.82–1.130.7
WBC, continuous1.060.89–1.220.51.000.86–1.140.9
Plts, continuous0.910.87–1.110.20.970.90–1.170.3

Abbreviations: ALC: absolute lymphocyte count; ANC: absolute neutrophil count; AMC: absolute monocyte count; CR: complete remission; IPS: international prognostic score; PR: partial response; Plts: platelets; WBC: white blood cell count.